Borregaard ASA reported EBITDA of NOK 515 million in the second quarter of 2026, slightly down from NOK 522 million a year earlier, as higher sales volume in BioSolutions was offset by increased energy costs, negative currency effects, and a less favourable product mix. Operating revenues rose to NOK 2,114 million from NOK 2,045 million, with improved results in BioMaterials and Fine Chemicals but a decline in BioSolutions. The company recorded a NOK 337 million impairment on its investment in Alginor ASA and NOK 30 million in other expenses for ground stabilisation at its Sarpsborg site, leading to a loss before tax of NOK 45 million compared with a profit of NOK 326 million in the prior-year period. Excluding those items, earnings per share were NOK 2.35. Borregaard is implementing a cost improvement programme targeting annual savings of NOK 150 million, with full effect expected from 2028.
Borregaard ASAEBITDA slightly down, impairment and other expenses lead to loss before tax, though cost programme announced.
Borregaard recorded a NOK 337 million impairment on its investment in Alginor ASA.